377 related articles for article (PubMed ID: 22616724)
1. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
2. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
3. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
4. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
5. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
Burger JA
Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
[TBL] [Abstract][Full Text] [Related]
6. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
Davids MS; Brown JR
Hematol Oncol Clin North Am; 2013 Apr; 27(2):329-39. PubMed ID: 23561476
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
9. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
10. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
Mráz M; Doubek M; Mayer J
Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM; Cosimo E; Leach MT; Michie AM
Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
[TBL] [Abstract][Full Text] [Related]
13. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
14. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
16. B cell receptor signaling in chronic lymphocytic leukemia.
Burger JA; Chiorazzi N
Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner A
Blood; 2012 Dec; 120(24):4684-91. PubMed ID: 22875912
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
19. Chronic Lymphocytic Leukemia: Disease Biology.
Koehrer S; Burger JA
Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
[TBL] [Abstract][Full Text] [Related]
20. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
